in silico bio-evolutio in silico bio-evolutio - novel AI paradigm for molecular biology
- Coordinator
- Camino Science Sp. Z O.o., Poland
- Runs
- 1 January 2023 to 31 May 2025
- Status
- Running
- EU funding
- €1.7m
- Total cost
- €2.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190103838
What the project is doing
In the project's own words, from its summary on CORDIS.
The success of phage therapies relies on correctly matching a therapeutic phage to bacterial strain. However calibration of therapy recipe may last for years. Presented solution enable to accelerate this by in silico simulations on AI platform for in vitro. It is able to find optimal phage that meets the phenotype imposed by the researcher, especially: -predict given phage effectiveness against a specific bacteria strain,-indicate mutations that increase phage effectiveness,-generate explanations for predictions.
Currently, this process is performed by wet-lab employees (in vitro). Replacing it with an in silico process will reduce the number 90 out of 100 experiments, significantly accelerating the process and improving phage therapy quality. At the same time, its the basis for modern probiotics (for microbiome modulation). At the same time, it will enable dynamically generate personalized therapies for specific patients. It is a novel endeavor in the area of molecular biology.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Camino Science Sp. Z O.o. | Biaystok | Poland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI